ArticleJournal of cancer research and clinical oncology2017

Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.

Zhaoxiong Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.